Triple Therapy Boosts Anaplastic Thyroid Cancer Survival Triple Therapy Boosts Anaplastic Thyroid Cancer Survival

With the neoadjuvant regimen of pembrolizumab added to dabrafenib and trametinib, survival in BRAF-mutated forms of the highly aggressive cancer can go from months to more than 5 years.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news